Clinical Trial Results: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adding oral atogepant to onabotulinumtoxinA (BOTOX) in adults with chronic migraine; results posted following completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Atogepant (Atogepant)
• OnabotulinumtoxinA (botulinum toxin type A)

Snippet

Sponsor: AbbVie | Conditions: Chronic Migraine | Phase 3 | Status: COMPLETED | Results posted: 2026-06-16